This week's movers and shakers in outsourcing have joined PPD and Recipharm.
Pharmaceutical Product Development (PPD) has appointed Michael Pollock VP of real world outcomes. The role covers health outcomes and evidence-based medicine, helping clients improve market and patient access to new drugs.
“Michael brings a unique background to this role, having held senior positions both in sales and marketing, and in health economics for both large pharmaceutical and biotechnology companies,” said Rob Dow, PPD’s senior VP of medical affairs.
The new VP was previously President of Reynolds Pollock & Associates, a health outcomes research and market access strategy consultancy. He has worked in the biopharmaceutical industry as VP of global health economics at Biogen Idec, VP of sales and marketing at Elan Pharmaceuticals, and VP of sales and marketing and information services at Bristol-Myers Squibb’s oncology therapeutics network.
PPD, along with Clinical Research Management (ClinicalRM) was last week awarded a contract with Biomedical Advanced Research and Development Authority (BARDA) to develop antidotes to medical warfare and pandemics.
Copyright - Unless otherwise stated all contents of this web site are © 2014 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Recipharm, Catalent, INC and PRA completed eye-catching IPOs in 2014. Which firms are likely follow suit in 2015?
Catering for low value, high volume customers as well as the growing number of firms developing complex...
Clinverse, Intertek and inVentiv are among the pharma services companies announcing new staff this week.